ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Fundamental Analysis

NASDAQ:ARTV • US04317A1079

5.68 USD
+0.23 (+4.22%)
Last: Feb 27, 2026, 01:33 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ARTV scores 3 out of 10 in our fundamental rating. ARTV was compared to 521 industry peers in the Biotechnology industry. ARTV has a great financial health rating, but its profitability evaluates not so good. ARTV is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ARTV has reported negative net income.
  • In the past year ARTV has reported a negative cash flow from operations.
ARTV Yearly Net Income VS EBIT VS OCF VS FCFARTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • ARTV has a Return On Assets (-53.20%) which is in line with its industry peers.
  • With a decent Return On Equity value of -61.28%, ARTV is doing good in the industry, outperforming 60.46% of the companies in the same industry.
Industry RankSector Rank
ROA -53.2%
ROE -61.28%
ROIC N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARTV Yearly ROA, ROE, ROICARTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ARTV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTV Yearly Profit, Operating, Gross MarginsARTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ARTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ARTV has more shares outstanding
  • Compared to 1 year ago, ARTV has a worse debt to assets ratio.
ARTV Yearly Shares OutstandingARTV Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M
ARTV Yearly Total Debt VS Total AssetsARTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • ARTV has an Altman-Z score of 0.22. This is a bad value and indicates that ARTV is not financially healthy and even has some risk of bankruptcy.
  • ARTV has a better Altman-Z score (0.22) than 60.65% of its industry peers.
  • ARTV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.22
ROIC/WACCN/A
WACC8.66%
ARTV Yearly LT Debt VS Equity VS FCFARTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • ARTV has a Current Ratio of 11.65. This indicates that ARTV is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 11.65, ARTV belongs to the best of the industry, outperforming 86.18% of the companies in the same industry.
  • A Quick Ratio of 11.65 indicates that ARTV has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 11.65, ARTV belongs to the best of the industry, outperforming 86.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11.65
Quick Ratio 11.65
ARTV Yearly Current Assets VS Current LiabilitesARTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • ARTV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.09%.
  • ARTV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
  • ARTV shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -49.95% yearly.
EPS 1Y (TTM)7.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.86%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ARTV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.25% yearly.
  • The Revenue is expected to grow by 189.66% on average over the next years. This is a very strong growth
EPS Next Y35.88%
EPS Next 2Y17.05%
EPS Next 3Y17.4%
EPS Next 5Y8.25%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.66%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ARTV Yearly Revenue VS EstimatesARTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2028 2029 2030 2031 2032 2033 200M 400M 600M
ARTV Yearly EPS VS EstimatesARTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARTV. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARTV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTV Price Earnings VS Forward Price EarningsARTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTV Per share dataARTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ARTV's earnings are expected to grow with 17.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.05%
EPS Next 3Y17.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ARTV does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV (2/27/2026, 1:33:02 PM)

5.68

+0.23 (+4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-23
Inst Owners69.44%
Inst Owner Change-6.74%
Ins Owners5.1%
Ins Owner Change22.2%
Market Cap139.39M
Revenue(TTM)N/A
Net Income(TTM)-79.19M
Analysts85
Price Target17.34 (205.28%)
Short Float %1.16%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.45%
Min EPS beat(2)-5.74%
Max EPS beat(2)0.83%
EPS beat(4)2
Avg EPS beat(4)-1.28%
Min EPS beat(4)-14.53%
Max EPS beat(4)14.3%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.02%
EPS NY rev (1m)0%
EPS NY rev (3m)2.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)-3.23
FCFYN/A
OCF(TTM)-3.14
OCFYN/A
SpS0
BVpS5.27
TBVpS5.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.2%
ROE -61.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.23%
ROA(5y)N/A
ROE(3y)-55.15%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.65
Quick Ratio 11.65
Altman-Z 0.22
F-Score4
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)238.05%
Cap/Depr(5y)N/A
Cap/Sales(3y)131.08%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.86%
EPS Next Y35.88%
EPS Next 2Y17.05%
EPS Next 3Y17.4%
EPS Next 5Y8.25%
Revenue 1Y (TTM)-100%
Revenue growth 3Y-49.95%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y189.66%
EBIT growth 1Y-8.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.03%
OCF growth 3YN/A
OCF growth 5YN/A

ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ

What is the ChartMill fundamental rating of ARTIVA BIOTHERAPEUTICS INC (ARTV) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ARTV.


Can you provide the valuation status for ARTIVA BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ARTIVA BIOTHERAPEUTICS INC (ARTV). This can be considered as Overvalued.


What is the profitability of ARTV stock?

ARTIVA BIOTHERAPEUTICS INC (ARTV) has a profitability rating of 1 / 10.


How financially healthy is ARTIVA BIOTHERAPEUTICS INC?

The financial health rating of ARTIVA BIOTHERAPEUTICS INC (ARTV) is 7 / 10.